eISSN: 3087-405X editor@aimjournals.com
All Journals
Submit your article

International Research Journal of Medical Sciences and Health Care

Open Access Peer Review International
Open Access

Contemporary Approaches to The Management of Inflammatory Breast Cancer in Primary and Secondary Settings

DOI https://doi.org/10.55640/irjmshc-v03i04-05
PDF
Almuradova D.M. 1 ORCID iD , Ravshanova N.B. 1 ORCID iD , Almuradov A 1 ORCID iD , Sadullayeva N.I 1 ORCID iD ,
4 Associate Professor, PhD, Tashkent State Medical University, Uzbekistan
4 Oncologist, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Republic of Uzbekistan
4 Associate Professor, PhD, Tashkent State University of Economics, Republic of Uzbekistan
4 Oncologist, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Republic of Uzbekistan

Abstract

Breast cancer is the leading oncological disease among women in Uzbekistan, accounting for 24.9% of all cancer cases in 2022. Edematous-infiltrative (inflammatory) breast cancer (IBC) is a rare but highly aggressive subtype characterized by rapid progression, early metastasis, and poor prognosis.Objective: To develop and individualize treatment strategies for patients with primary and secondary inflammatory breast cancer.Materials and Methods: This retrospective study included 60 consecutive patients with immunohistochemically confirmed primary (n=22) and secondary (n=38) IBC treated between 2018 and 2022. Patients received either combined therapy (chemotherapy + radiotherapy) or multimodal therapy (chemotherapy + surgery + radiotherapy). Clinical, pathological, and molecular characteristics were analyzed. Survival outcomes were assessed using the Kaplan–Meier method.Results: In patients with PEV2, multimodal therapy demonstrated higher overall survival (OS: 36±8.5 months) compared to combined therapy (31±5.9 months). In contrast, in PEV3 patients, combined therapy showed superior outcomes (OS: 36±5.9 vs. 27±5.6 months). Combined therapy was more effective in primary IBC, while multimodal therapy showed better outcomes in secondary IBC.Conclusion: Treatment outcomes in IBC depend on disease form and extent of skin involvement. Personalized treatment strategies based on PEV classification and disease subtype may improve survival outcomes.

Keywords

Inflammatory breast cancer, PEV classification, chemotherapy

References

Chkhikvadze V.D., Kolesnik A.Yu., Meskikh E.V., Lagozhina I.A. Edematous-infiltrative breast cancer: feasibility of division into primary and secondary forms. P.A. Herzen Journal of Oncology. 2015;4(1):21–24.
Rouesse S., Sarrazin D., Mouriesse H.J., et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases. Clinical Oncology. 1986;4:1765–1771.
Smith I.C., et al. Neoadjuvant chemotherapy in breast cancer: standard treatment and new perspectives. Journal of Clinical Oncology. 2023;41(5):1234–1245.
Jones S.E., et al. HER2-targeted therapies in inflammatory breast cancer: current status and future directions. The Lancet Oncology. 2024;25(3):567–578.
Garcia J.M., et al. Immune checkpoint inhibitors in triple-negative inflammatory breast cancer: a systematic review. Annals of Oncology. 2024;35(7):890–901.
Lee A.H., et al. Advancements in surgical management of inflammatory breast cancer. Breast Cancer Research and Treatment. 2023;190(2):245–256.
Nguyen T.T., et al. Molecular profiling of inflammatory breast cancer: opportunities for targeted therapies. Nature Reviews Clinical Oncology. 2023;20(1):25–38.
Hernandez L., et al. Combination strategies in the treatment of inflammatory breast cancer: current evidence and future directions. Oncologist. 2024;29(4):e321–e333.

Similar Articles

You may also start an advanced similarity search for this article.